The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage

Launched by ASSIUT UNIVERSITY · Aug 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new blood markers called T Immunoglobulin G and T Immunoglobulin M to help doctors better diagnose and monitor Systemic Lupus Erythematosus (SLE), a disease where the immune system mistakenly attacks the body. These markers are related to certain immune cells called T cells, which play an important role in how SLE develops and causes symptoms. The goal is to see if these markers can give clearer information about how active the disease is and whether it is causing damage, which could help doctors make faster and more accurate diagnoses.

Adults with SLE who meet specific diagnostic criteria (set by experts in 2019) can take part in this study. People with other autoimmune diseases, or who are pregnant or breastfeeding, are not eligible. Participants will likely provide blood samples for testing and share information about their symptoms and health. This research could improve care for people with lupus by offering new tools to track the disease and tailor treatments more effectively. The study is not yet open for enrollment but is planned for adults aged 18 and older of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • : Adult SLE Patients ( \>18 years ) who are fulfilling the 2019 ACR\\EULAR classification criteria of systemic lupus erythematosus
• Exclusion Criteria:
• • 1. SLE patients \<18 years old
• • 2. Patients with other autoimmune diseases (systemic sclerosis , sjogren syndrome, rheumatoid arthritis dermatomyositis, mixed connective tissue disease).
• • 3. Pregnant and lactating women .
• • -